GAIN THERAPEUTICS INC (GANX) Fundamental Analysis & Valuation

NASDAQ:GANX • US36269B1052

Current stock price

2.43 USD
-0.32 (-11.64%)
At close:
2.459 USD
+0.03 (+1.19%)
After Hours:

This GANX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. GANX Profitability Analysis

1.1 Basic Checks

  • In the past year GANX has reported negative net income.
  • In the past year GANX has reported a negative cash flow from operations.
  • In the past 5 years GANX always reported negative net income.
  • GANX had a negative operating cash flow in each of the past 5 years.
GANX Yearly Net Income VS EBIT VS OCF VS FCFGANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • GANX's Return On Assets of -189.07% is on the low side compared to the rest of the industry. GANX is outperformed by 87.64% of its industry peers.
  • GANX has a Return On Equity of -503.05%. This is in the lower half of the industry: GANX underperforms 76.06% of its industry peers.
Industry RankSector Rank
ROA -189.07%
ROE -503.05%
ROIC N/A
ROA(3y)-120.33%
ROA(5y)-86.78%
ROE(3y)-182.77%
ROE(5y)-129.19%
ROIC(3y)N/A
ROIC(5y)N/A
GANX Yearly ROA, ROE, ROICGANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for GANX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GANX Yearly Profit, Operating, Gross MarginsGANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. GANX Health Analysis

2.1 Basic Checks

  • GANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, GANX has more shares outstanding
  • Compared to 5 years ago, GANX has more shares outstanding
  • GANX has a worse debt/assets ratio than last year.
GANX Yearly Shares OutstandingGANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
GANX Yearly Total Debt VS Total AssetsGANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • GANX has an Altman-Z score of -9.18. This is a bad value and indicates that GANX is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of GANX (-9.18) is worse than 71.24% of its industry peers.
  • GANX has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.09, GANX is not doing good in the industry: 61.20% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -9.18
ROIC/WACCN/A
WACC8.89%
GANX Yearly LT Debt VS Equity VS FCFGANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 1.79 indicates that GANX should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.79, GANX is doing worse than 78.19% of the companies in the same industry.
  • A Quick Ratio of 1.79 indicates that GANX should not have too much problems paying its short term obligations.
  • GANX has a Quick ratio of 1.79. This is in the lower half of the industry: GANX underperforms 77.03% of its industry peers.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.79
GANX Yearly Current Assets VS Current LiabilitesGANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. GANX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 47.86% over the past year.
  • The Revenue for GANX has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)47.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • GANX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.02% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.49%
EPS Next 2Y10.09%
EPS Next 3Y-0.26%
EPS Next 5Y10.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GANX Yearly Revenue VS EstimatesGANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2029 2030 2031 2032 2033 100M 200M 300M 400M
GANX Yearly EPS VS EstimatesGANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. GANX Valuation Analysis

4.1 Price/Earnings Ratio

  • GANX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year GANX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GANX Price Earnings VS Forward Price EarningsGANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GANX Per share dataGANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.09%
EPS Next 3Y-0.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GANX Dividend Analysis

5.1 Amount

  • GANX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GANX Fundamentals: All Metrics, Ratios and Statistics

GAIN THERAPEUTICS INC

NASDAQ:GANX (3/13/2026, 8:00:00 PM)

After market: 2.459 +0.03 (+1.19%)

2.43

-0.32 (-11.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-19
Inst Owners21.02%
Inst Owner Change49.55%
Ins Owners2.61%
Ins Owner Change0%
Market Cap93.46M
Revenue(TTM)N/A
Net Income(TTM)-18.59M
Analysts85.45
Price Target7.75 (218.93%)
Short Float %8.18%
Short Ratio2.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.1%
Min EPS beat(2)-10.66%
Max EPS beat(2)12.85%
EPS beat(4)3
Avg EPS beat(4)16.46%
Min EPS beat(4)-10.66%
Max EPS beat(4)41.18%
EPS beat(8)5
Avg EPS beat(8)-0.57%
EPS beat(12)6
Avg EPS beat(12)-7.64%
EPS beat(16)8
Avg EPS beat(16)-4.54%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)11.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 25.29
P/tB 26.19
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0
BVpS0.1
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -189.07%
ROE -503.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.33%
ROA(5y)-86.78%
ROE(3y)-182.77%
ROE(5y)-129.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.79
Quick Ratio 1.79
Altman-Z -9.18
F-Score3
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)81.72%
Cap/Depr(5y)179.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
EPS Next Y28.49%
EPS Next 2Y10.09%
EPS Next 3Y-0.26%
EPS Next 5Y10.02%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.3%
OCF growth 3YN/A
OCF growth 5YN/A

GAIN THERAPEUTICS INC / GANX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for GAIN THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to GANX.


What is the valuation status of GAIN THERAPEUTICS INC (GANX) stock?

ChartMill assigns a valuation rating of 0 / 10 to GAIN THERAPEUTICS INC (GANX). This can be considered as Overvalued.


Can you provide the profitability details for GAIN THERAPEUTICS INC?

GAIN THERAPEUTICS INC (GANX) has a profitability rating of 0 / 10.


Can you provide the financial health for GANX stock?

The financial health rating of GAIN THERAPEUTICS INC (GANX) is 1 / 10.


What is the earnings growth outlook for GAIN THERAPEUTICS INC?

The Earnings per Share (EPS) of GAIN THERAPEUTICS INC (GANX) is expected to grow by 28.49% in the next year.